Yan Wang

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 34

Top Venues

Thoracic cancer

Cancer medicine

Biomedicines

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Si-Yu Lei, Hai-Yan Xu, Yan Wang
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. Thoracic cancer (2023)
Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wang
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer (2023)
Yaning Yang, Guangjian Yang, Weihua Li, Haiyan Xu, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Yan Wang
Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner. Future oncology (London, England) (2023)
Hong-Shuai Li, Cheng-Ming Liu, Yan Wang
RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma. Thoracic cancer (2023)
Dongyu Li, Jingnan Wang, Chengming Liu, Yuejun Luo, Haiyan Xu, Yan Wang, Nan Sun, Jie He
Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs. Biomedicines 11 (4) (2023)
Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wang
The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer medicine (2023)
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer. Thoracic cancer (2023)
Fei Xu, Jun-Ling Li, Pu-Yuan Xing, Yutao Liu, Yan Wang
Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse. Cancer medicine (2023)
Dongyu Li, Jingnan Wang, Chengming Liu, Yuejun Luo, Haiyan Xu, Yan Wang, Nan Sun, Jie He
Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs. Biomedicines 11 (4) (2023)
Fei Xu, Heng-Chi Chen, Hai-Yan Xu, Jun-Ling Li, Xuezhi Hao, Pu-Yuan Xing, Jianming Ying, Yan Wang
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 13 (22) (2022)
Hong-Shuai Li, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, Li-Qiang Zhou, Peng Liu, Yu-Ying Wang, Xing-Sheng Hu, Pu-Yuan Xing, Yan Wang
Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). Cancers 14 (21) (2022)
Yaning Yang, Xin Ai, Hai-Yan Xu, Guangjian Yang, Lu Yang, Xuezhi Hao, Ke Yang, Yuling Mi, Guizhen Wang, Shuyang Zhang, Siyu Lei, Yan Wang
Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice. Thoracic cancer 13 (23) (2022)
Hong-Shuai Li, Jin-Yao Zhang, Xiang Yan, Hai-Yan Xu, Xue-Zhi Hao, Pu-Yuan Xing, Yan Wang
A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. Cancer medicine 11 (4) (2022)
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei, Yan Wang
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. Cancer medicine (2022)
Shuyang Zhang, Lu Yang, Yaning Yang, Ying Xin, Yan Wang
An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer. Thoracic cancer 13 (23) (2022)
Chengming Liu, Sufei Zheng, Zhanyu Wang, Sihui Wang, Xinfeng Wang, Lu Yang, Haiyan Xu, Zheng Cao, Xiaoli Feng, Qi Xue, Yan Wang, Nan Sun, Jie He
KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer communications (London, England) 42 (9) (2022)
Hong-Shuai Li, Cheng-Ming Liu, Yan Wang
Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer. Future oncology (London, England) 18 (19) (2022)
Tongji Xie, Zhenghao Liu, Yan Li, Shou-Zheng Wang, Yixin Zhai, Fei Teng, Xuezhi Hao, Yan Wang, Hongyu Wang, Xin Zhang, Xi Wu, Jianming Ying, Jun-Ling Li, Ye Zhang, Yuefei Deng, Pu-Yuan Xing
Evolutionary characteristics and immunological divergence of lung and brain metastasis lesions in NSCLC. Molecular cancer research : MCR (2022)
Shuyang Zhang, Huihui Yin, Jing Zhang, Lu Yang, Guangjian Yang, Jia Jia, Yuchen Jiao, Jianming Ying, Yan Wang
Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung. Thoracic cancer 12 (20) (2021)
Hai-Yan Xu, Weihua Li, Guangjian Yang, Junling Li, Lu Yang, Fei Xu, Yaning Yang, Jianming Ying, Yan Wang
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. Targeted oncology 15 (3) (2021)
Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xing-Sheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Jun-Ling Li
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic cancer 12 (21) (2021)
Huihui Yin, Lu Yang, Gongxin Peng, Ke Yang, Yuling Mi, Xingsheng Hu, Xuezhi Hao, Yuchen Jiao, Xiao-Bing Wang, Yan Wang
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. Cancer biology & medicine (2021)
Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, Shuyang Zhang, Xin Ai, Shucai Zhang, Yan Wang
Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients. Cancer medicine 10 (23) (2021)
Li-Ling Huang, Xing-Sheng Hu, Yan Wang, Jun-Ling Li, Hong-Yu Wang, Peng Liu, Jian-Ping Xu, Xiao-Hui He, Xue-Zhi Hao, Pei-Di Jiang, Yu-Tao Liu, Jian Luo, Sheng-Yu Zhou, Jin-Wan Wang, Jian-Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuan-Kai Shi
Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic cancer 12 (13) (2021)
Yuequan Shi, Jian Fang, Cheng-Zhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Min-Jiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thoracic cancer 13 (3) (2021)
Lu Yang, Xuezhi Hao, Xingsheng Hu, Zhijie Wang, Ke Yang, Yuling Mi, Yaning Yang, Hai-Yan Xu, Guangjian Yang, Yan Wang
Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thoracic cancer 11 (12) (2020)
Lu Yang, Chong Pang, Fei Xu, Guangjian Yang, Hai-Yan Xu, Chang-Li Wang, Yan Wang
Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. Cancer management and research 12 (2020)
Hai-Yan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying, Shucai Zhang, Yan Wang
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. Cancer medicine 9 (10) (2020)
Fei Xu, Guangjian Yang, Hai-Yan Xu, Lu Yang, Weini Qiu, Yan Wang
Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thoracic cancer 11 (3) (2020)
Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. Cancer medicine 8 (13) (2019)

Yan Wang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yan Wang